Royal Cornwall Hospitals Trust Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2019
NCT03963102
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Royal Cornwall Hospitals Trust

Active Ingredients

Drugs in Phase 3 Trials (1)

aminolevulinic acid (levulan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1